keyword
MENU ▼
Read by QxMD icon Read
search

Alopecia chemotherapy

keyword
https://www.readbyqxmd.com/read/30508810/unusual-maculopapular-rash-on-the-scalp-of-a-patient-with-mediterranean-spotted-fever
#1
Ivan Baltadzhiev, Nedialka Popivanova
OBJECTIVE: To report a rare case of maculopapular rash on the scalp in a patient with Mediterranean spotted fever (MSF). CLINICAL PRESENTATION AND INTERVENTION: A 58-year-old woman with breast cancer and chemotherapy-induced alopecia contracted MSF. Her clinical features were typical, except for a maculopapular rash covering the scalp. The diagnosis of MSF was confirmed by the immunofluorescent assay. The disease had a favorable course and the patient was discharged in a good condition...
December 3, 2018: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
https://www.readbyqxmd.com/read/30463345/annurca-apple-polyphenols-protect-murine-hair-follicles-from-taxane-induced-dystrophy-and-hijacks-polyunsaturated-fatty-acid-metabolism-toward-%C3%AE-oxidation
#2
Gennaro Riccio, Eduardo Sommella, Nadia Badolati, Emanuela Salviati, Sara Bottone, Pietro Campiglia, Monica Dentice, Gian Carlo Tenore, Mariano Stornaiuolo, Ettore Novellino
Chemotherapy-induced alopecia (CIA) is a common side effect of conventional chemotherapy and represents a major problem in clinical oncology. Even months after the end of chemotherapy, many cancer patients complain of hair loss, a condition that is psychologically difficult to manage. CIA disturbs social and sexual interactions and causes anxiety and depression. Synthetic drugs protecting from CIA and endowed with hair growth stimulatory properties are prescribed with caution by oncologists. Hormones, growth factors, morphogens could unwontedly protect tumour cells or induce cancer cell proliferation and are thus considered incompatible with many chemotherapy regimens...
November 20, 2018: Nutrients
https://www.readbyqxmd.com/read/30457055/hair-loss-prevention-by-a-scalp-cooling-device-in-early-breast-cancer-patients-the-poliambulanza-preliminary-experience
#3
Tiziana Prochilo, Alessandra Huscher, Federica Andreis, Mara Mirandola, Elisabetta Zaina, Barbara Pomentale, Chiara Pedrali, Laura Zanotti, Stefano Mutti, Alberto Zaniboni
BACKGROUND: The most effective agents in the treatment of breast cancer have as common side effect the hair loss. Some studies reported a reduction of hair loss with the use of the scalp cooling device. Indeed, it decreases the drug accumulation in the hair follicles. We report our preliminary experience with a scalp cooling device in reducing chemotherapy-induced alopecia and related distress in breast cancer patients undergoing adjuvant chemotherapy. METHODS: Hair loss grading and treatment tolerability were evaluated during chemotherapy every 21 days and 3 weeks after the last cycle of chemotherapy via Dean's scale by patients and operators and a comfort analogic scale by patients...
November 19, 2018: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/30429032/pembrolizumab-and-platinum-based-chemotherapy-as-first-line-therapy-for-advanced-non-small-cell-lung-cancer-phase-1-cohorts-from-the-keynote-021-study
#4
Shirish M Gadgeel, James P Stevenson, Corey J Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza C Villaruz, Matthew Gubens, Ralph Hauke, James Chih-Hsin Yang, Lecia V Sequist, Robert Bachman, Sanatan Saraf, Harry Raftopoulos, Vassiliki Papadimitrakopoulou
OBJECTIVES: Platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In cohorts A-C of the multicohort phase 1/2 study KEYNOTE-021 (Clinicaltrials.gov, NCT02039674), we evaluated combinations of platinum-doublet chemotherapy with the anti-programmed death 1 monocloncal antibody pembrolizumab. MATERIALS AND METHODS: Patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations were randomized to pembrolizumab 2 or 10 mg/kg Q3W plus carboplatin area under the serum concentration-time curve (AUC) 6 mg/mL/min plus paclitaxel 200 mg/m2 (cohort A, any histology), carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m2 plus bevacizumab 15 mg/kg (cohort B, non-squamous), or carboplatin AUC 5 mg/mL/min plus pemetrexed 500 mg/m2 (cohort C, non-squamous) for 4 cycles followed by maintenance pembrolizumab (cohort A), pembrolizumab plus bevacizumab (cohort B), or pembrolizumab plus pemetrexed (cohort C)...
November 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/30397477/gemcitabine-induced-skin-necrosis
#5
Maria Monica Haydock, Saroj Sigdel, Toni Pacioles
Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar-plantar erythrodysesthesia. Skin necrosis is a very rare adverse effect of this otherwise well-tolerated chemotherapeutic agent. In searching the literature, only one other case has been reported...
2018: SAGE Open Medical Case Reports
https://www.readbyqxmd.com/read/30383138/evaluation-of-prevention-interventions-for-taxane-induced-dermatologic-adverse-events-a-systematic-review
#6
Dustin H Marks, Azam Qureshi, Adam Friedman
Importance: Chemotherapy-induced alopecia as well as nail and cutaneous changes occur in up to 89% of patients receiving taxane-based chemotherapy and are associated with cosmetic concerns, psychosocial distress, and overall morbidity. Objective: To review the efficacy and safety of interventions to prevent taxane-induced dermatologic adverse events. Evidence Review: PubMed and Scopus databases were systematically reviewed for studies published in the English language from January 1, 1980, to August 13, 2018...
October 31, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/30374901/toxic-side-effects-of-targeted-therapies-and-immunotherapies-affecting-the-skin-oral-mucosa-hair-and-nails
#7
REVIEW
Mario Lacouture, Vincent Sibaud
Targeted therapies and immunotherapies are associated with a wide range of dermatologic adverse events (dAEs) resulting from common signaling pathways involved in malignant behavior and normal homeostatic functions of the epidermis and dermis. Dermatologic toxicities include damage to the skin, oral mucosa, hair, and nails. Acneiform rash is the most common dAE, observed in 25-85% of patients treated by epidermal growth factor receptor and mitogen-activated protein kinase kinase inhibitors. BRAF inhibitors mostly induce secondary skin tumors, squamous cell carcinoma and keratoacanthomas, changes in pre-existing pigmented lesions, as well as hand-foot skin reactions and maculopapular hypersensitivity-like rash...
October 30, 2018: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/30333277/an-interesting-case-of-hepatic-adrenocortical-carcinoma
#8
Hikmat Permana, Guntur Darmawan, Ervita Ritonga, Maya Kusumawati, Miftahurachman Miftahurachman, Nanny Natalia Soetedjo
Adrenocortical carcinoma (ACC) is a rare solid tumor with an incidence of 0.5 to 2 cases per million per year. It affects women more commonly than men with a ratio of 1.5:1. Ectopic ACC are considered to be extremely rare with no exact incidence data yet. We report an interesting case of hepatic ACC in a young woman with clinical signs of virilization.A-21-year old Sundanese woman visited our endocrine clinic with progressive hirsutism over the face, body, and extremities starting 14 years previously. She had irregular, heavy periods when she was 7 years old...
July 2018: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/30280054/persistent-alopecia-in-a-breast-cancer-patient-following-taxane-chemotherapy-and-adjuvant-endocrine-therapy-case-report-and-review-of-post-treatment-hair-loss-in-oncology-patients-with-breast-cancer
#9
Tyler Werbel, Philip R Cohen
Taxane chemotherapy and adjuvant endocrine therapy are commonly used in breast cancer patients following surgery. We describe a 59-year-old woman with a triple-positive invasive right breast cancer that was treated with surgery, radiation, chemotherapy, and adjuvant hormonal therapy. She subsequently developed scalp alopecia, with histopathological features of both androgenetic alopecia and alopecia areata; the hair loss did not resolve after completion of her chemotherapy. Significant clinical improvement was observed with topical minoxidil therapy...
July 27, 2018: Curēus
https://www.readbyqxmd.com/read/30272196/combination-of-transarterial-chemoembolization-and-sorafenib-improves-outcomes-of-unresectable-hepatocellular-carcinoma-an-updated-systematic-review-and-meta-analysis
#10
Piao-Piao Jin, Shi-Yi Shao, Wang-Teng Wu, Xin-Yu Zhao, Bing-Feng Huang, Qi-Han Fu, Ri-Sheng Que, Qi-Da Hu
Background: The effectiveness of combination therapy of transarterial chemoembolization and sorafenib for unresectable hepatocellular carcinoma are controversial in some studies. This meta-analysis aims to compare efficacy and safety, as well as regional disparities, between transarterial chemoembolization plus sorafenib and transarterial chemotherapy alone for hepatocellular carcinoma. Methods: We systematically searched multiple databases to select eligible studies...
December 1, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/30269322/-short-term-efficacy-and-safety-of-the-synchronous-neoadjuvant-chemoradiotherapy-with-paclitaxel-plus-carboplatin-in-stage-iii-adenocarcinoma-of-esophagogastric-junction
#11
RANDOMIZED CONTROLLED TRIAL
Yangyang Ji, Tao Peng, Guoqiang Wang, Yu Zhang, Mingfu Cao, Qiang Gao, Shuguang Li
OBJECTIVE: To evaluate the short-term efficacy and safety of neoadjuvant synchronous chemoradiotherapy (paclitaxel plus carboplatin regimen) in stage III adenocarcinoma of esophagogastric junction (AEG). METHODS: Forty cases clinically diagnosed as stage III AEG were prospectively enrolled at the Department of Gastrointestinal Oncology Surgery, the First Affiliated Hospital of Hebei North University from December 2014 to November 2017 and then were randomly divided into paclitaxel plus carboplatin combined with synchronous radiotherapy group(neoadjuvant group) and direct operation group...
September 25, 2018: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/30255454/coolhair-a-prospective-randomized-trial-to-investigate-the-efficacy-and-tolerability-of-scalp-cooling-in-patients-undergoing-neo-adjuvant-chemotherapy-for-early-breast-cancer
#12
Katharina Smetanay, Philippe Junio, Manuel Feißt, Julia Seitz, Jessica Cecile Hassel, Luisa Mayer, Lina Maria Matthies, Arina Schumann, André Hennigs, Jörg Heil, Christof Sohn, Dirk Jaeger, Andreas Schneeweiss, Frederik Marmé
PURPOSE: Chemotherapy-induced alopecia (CIA) is a distressing side effect for women with breast cancer undergoing chemotherapy. Scalp cooling is a method aiming to prevent CIA, but its efficacy is not well defined. Randomized trials until recently and at the time this trial was designed have been lacking. METHODS: Patients undergoing (neo)adjuvant chemotherapy for early breast cancer (EBC) were randomized to scalp cooling (CAP) or observation (NoCAP). All patients received 18-24 weeks of anthracycline- and/or taxane-based chemotherapy...
September 25, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/30239512/scalp-cooling-implementation-of-a-program-at-a-multisite-organization
#13
Erica Fischer-Cartlidge, Mikel Ross, Karen Hernández, Ashley Featherstone, Curt Haase
BACKGROUND: Chemotherapy-induced alopecia is a well-known side effect of some types of cancer treatments. With U.S. Food and Drug Administration clearance of two scalp cooling machines, patients with cancer now have the opportunity to minimize this hair loss. However, multiple barriers can exist for organizations when establishing a scalp cooling program. OBJECTIVES: This article describes the experience of a large multisite organization that implemented a machine-based scalp cooling program...
October 1, 2018: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/30235921/a-phase-ii-study-to-evaluate-the-safety-and-efficacy-of-pegteograstim-in-korean-breast-cancer-patients-receiving-dose-dense-doxorubicin-cyclophosphamide
#14
Gun Min Kim, Joo Hoon Kim, Ji Heung Jeong, Young Up Cho, Seung Il Kim, Seho Park, Hyung Seok Park, Ji Ye Kim, Joohyuk Sohn
Purpose: Dose-dense chemotherapy (DD-CT) is a preferred (neo) adjuvant regimen in early breast cancer (BC). Although the results of reported randomized trials are conflicting, a recent meta-analysis showed improved overall and disease-free survival with DD-CT compared to conventional schedules. However, no DD-CT safety data for Korean BC patients are available. This phase II study was conducted to evaluate the safety and efficacy of pegteograstim in Korean BC patients receiving DD-CT...
September 19, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/30233770/alopecia-areata-and-demyelination-as-paraneoplastic-manifestation-in-paediatric-hodgkin-s-lymphoma
#15
Shravan Kanaparthi, Shrikiran Aroor, Suneel C Mundkur, Sowmya Shashidhara, Kasi Viswanath Reddy
Hodgkin's Lymphoma is one of the commonly encountered lymphomas in childhood. Most of the children present with lymphadenopathy. A rare subset of children do present with constellation of atypical symptoms as paraneoplastic syndromes. We hereby present an 11-year-old boy with classical Hodgkin's Lymphoma associated with Alopecia areata and demyelination as paraneoplastic manifestations. Both these paraneoplastic manifestations improved after initiating chemotherapy (ABVD regimen). A high index of suspicion for underlying malignancy would help clinicians in clinching an early diagnosis and would avert the associated complications...
April 1, 2018: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/30120165/permanent-chemotherapy-induced-alopecia-in-patients-with-breast-cancer-a-3-year-prospective-cohort-study
#16
Danbee Kang, Im-Ryung Kim, Eun-Kyung Choi, Young Hyuck Im, Yeon Hee Park, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Hae Kwang Lee, Ji-Hye Park, Dong-Youn Lee, Mario E Lacouture, Eliseo Guallar, Juhee Cho
BACKGROUND: Although chemotherapy-induced alopecia (CIA) is considered temporary, some patients report persistent alopecia several years after chemotherapy. There is, however, a paucity of long-term prospective data on the incidence and impact of permanent CIA (PCIA). The objective of our study was to estimate the long-term incidence of PCIA in a cohort of patients with breast cancer whose hair volume and density were measured prior to chemotherapy and who were followed for 3 years after chemotherapy...
August 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30100379/sorafenib-plus-topotecan-versus-placebo-plus-topotecan-for-platinum-resistant-ovarian-cancer-trias-a-multicentre-randomised-double-blind-placebo-controlled-phase-2-trial
#17
Radoslav Chekerov, Felix Hilpert, Sven Mahner, Ahmed El-Balat, Philipp Harter, Nikolaus De Gregorio, Claudius Fridrich, Susanne Markmann, Jochem Potenberg, Ralf Lorenz, Guelten Oskay-Oezcelik, Marcus Schmidt, Petra Krabisch, Hans-Joachim Lueck, Rolf Richter, Elena Ioana Braicu, Andreas du Bois, Jalid Sehouli
BACKGROUND: Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. METHODS: We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously treated with two or fewer chemotherapy lines for recurrent disease were stratified (first vs later relapse) in block sizes of four and randomly assigned (1:1) using a web-generated response system to topotecan (1·25 mg/m2 on days 1-5) plus either oral sorafenib 400 mg or placebo twice daily on days 6-15, repeated every 21 days for six cycles, followed by daily maintenance sorafenib or placebo for up to 1 year in patients without progression...
September 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30098079/chemotherapy-induced-alopecia-the-urgent-need-for-treatment-options
#18
LETTER
M Sikora, L Rudnicka
No abstract text is available yet for this article.
August 11, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/30087568/comparable-efficacy-and-less-toxicity-of-pegylated-liposomal-doxorubicin-versus-epirubicin-for-neoadjuvant-chemotherapy-of-breast-cancer-a-case-control-study
#19
Minjun Dong, Liang Luo, Xiaogang Ying, Xianqiu Lu, Jianguo Shen, Zhinong Jiang, Linbo Wang
Background: Pegylated liposomal doxorubicin (PLD) and epirubicin are both superior variants of doxorubicin and are commonly applied as basic chemotherapeutics in breast cancer. However, the direct comparison of their efficacy and side effects has not been adequately reported. This study aimed to compare the efficacy and toxicity of PLD and epirubicin as neoadjuvant chemotherapy for invasive breast cancer. Patients and methods: Women (n = 43) with invasive breast cancer who received neoadjuvant chemotherapy with the regimens containing PLD (PLD group) were analyzed and 1:2 matched with those (n = 86) who received regimens containing epirubicin (epirubicin group) according to clinical TNM staging and taxane combination...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/30048865/efficacy-of-scalp-cooling-in-reducing-alopecia-in-early-breast-cancer-patients-receiving-contemporary-chemotherapy-regimens
#20
Arlene Chan, Astrid Bauwens, Sally Pontre, Sally Jackson, Frances McGlone, Tracie Ernenwein, Jun Chih, Christopher Reid
INTRODUCTION: Hair loss as a result of chemotherapy for early breast cancer (EBC) is a frequent and distressing side effect. Minimising hair loss may improve mood and body image. Our aim was to determine scalp cooling (SC) efficacy in EBC patients receiving contemporary chemotherapy regimen, to inform future patients choice to use SC or not. METHODS AND RESULTS: Prospective cohort study of 60 stage 1-3 EBC patients recommended to receive taxane or anthracycline-taxane chemotherapy regimens...
October 2018: Breast: Official Journal of the European Society of Mastology
keyword
keyword
158578
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"